Vimian Group AB (publ) (VIMGF)

OTCMKTS · Delayed Price · Currency is USD
3.010
-1.290 (-30.00%)
At close: Sep 10, 2025
-30.00%
Market Cap1.70B
Revenue (ttm)493.96M
Net Income (ttm)36.96M
Shares Outn/a
EPS (ttm)0.07
PE Ratio45.91
Forward PE25.51
Dividendn/a
Ex-Dividend Daten/a
Volume15,000
Average Volume6,643
Open2.850
Previous Close4.300
Day's Range2.850 - 3.010
52-Week Range2.850 - 4.500
Beta1.50
RSI42.44
Earnings DateFeb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I... [Read more]

Sector Healthcare
Founded 2020
Employees 1,200
Stock Exchange OTCMKTS
Ticker Symbol VIMGF
Full Company Profile

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR Financial Statements

News

Vimian Group AB (publ) (VIMGF) Q3 2025 Earnings Call Transcript

Vimian Group AB (publ) (OTCPK:VIMGF) Q3 2025 Earnings Call October 22, 2025 3:00 AM EDT Company Participants Carl Johan Boudrie - CFO & Interim CEO Magnus Kjellberg - Chief Executive Officer of Nextmu...

8 days ago - Seeking Alpha